Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third-quarter 2025 dividend of $0.43 per share. Alongside these developments, ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is embarking on a Phase 1 clinical study titled ‘A PHASE 1, ...

This article conducts technical analysis and provides forecasts for top trending stocks like Plug Power (PLUG), Uber, and ...

In the latest close session, Pfizer (PFE) was up +1.17% at $24.31. The stock outpaced the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 1.19%, and the Nasdaq, a tech-heavy index, added 1.43 ...

This was the stock's third consecutive day of gains.

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

However, its stock has struggled since 2021 when it hit its all-time high of $392.15 per share, falling 45.51% since. With the industry ripe for expansion, 24/7 Wall Street has performed an analysis ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside this ...